Nevertheless, our findings highlight the function of SA14 as a regulator of chemoresistance and immune surveillance and the potential utility of SA14 expression as a valuable biomarker in clinical studies, that is, loss of SA14 as an adverse prognostic factor in CRC patients and as a predictive biomarker for responsiveness to chemotherapy and anti‐PD‐L1‐based immunotherapy combination. This evidence concerns the gene CD274 and colorectal carcinoma.